ClinicalTrials.gg
CompletedNCT01243073ET/PVUpdated Jan 26, 2016

Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera

A Phase 2 interventional study of Imetelstat in Essential Thrombocythemia and Polycythemia Vera, sponsored by Geron Corporation. Completed at 12 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-26.

Sponsored by Geron Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 149 studies in Thrombocythemia, Essential with a site in United States — 18 open to participants now, 32 under way, 6 of them phase 3. Thrombocythemia, Essential · United States.

Enrollment
93rd of 120
20 · median 45
Started
2010
with 5 others
Phase 2
49 of 149
6 open now
Registered
95th of 149
by date

Among the 149 studies in Thrombocythemia, Essential with a site in United States, this one is the 93rd largest by enrollment of the 120 interventional ones that give a count, is one of 6 that started in 2010, is one of 49 in phase 2, and was the 95th registered.

Thrombocythemia, Essential

229 studies on the registry are indexed under Thrombocythemia, Essential; 38 are open to participants now.

Browse Thrombocythemia, Essential studies →

Open to participants now

18 of the 149 studies in Thrombocythemia, Essential with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Thrombocythemia, Essential studies recruiting now, 30 (88%) set no upper age limit and 3 (9%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Thrombocythemia, Essential with a site in United States, or all of them as a file.
02

Study summary

This is a phase II open-label study of single agent imetelstat in patients with essential thrombocytopenia or with polycythemia vera who have failed or are intolerant to at least one prior therapy, or who refuse standard therapy.

Read the detailed description

For patients with ET: To obtain a preliminary estimate of efficacy of imetelstat, as measured by best hematologic response within the first year of therapy in patients with ET who have failed or are intolerant to at least one prior therapy, or who have refused standard therapy.

For patients with PV: To obtain a preliminary estimate of efficacy of imetelstat, as measured by maintenance of Hct \< 45% in men and \< 42% in women (or pre-specified Hct count that is tolerable) without phlebotomy or myelosuppressive therapy within the first year of therapy in patients with PV who have failed or are intolerant to at least one prior therapy, or who have refused standard therapy.

03

Conditions studied

  • Essential Thrombocythemia
  • Polycythemia Vera

Keywords

  • imetelstat
  • imetelstat sodium
  • GRN163L
  • telomerase inhibitor
  • telomerase
  • essential thrombocytosis
  • essential thrombocythemia
  • ET
  • polycythemia vera
  • PV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

ET-Specific Criteria

  • Confirmed diagnosis of ET by WHO criteria
  • Patients with ET requiring cytoreduction who have failed or are intolerant to at least one prior therapy, or who refuse standard therapy
  • Laboratory criteria (within 14 days of first study drug administration):

    • > 600,000/μL
    • ≥ 1500/μL
    • ≥ 10 g/dL

PV-Specific Criteria

  • Confirmed diagnosis of PV by WHO criteria
  • Patients with PV requiring cytoreduction with phlebotomy and/or myelosuppressive agents

    • Patients may have failed or are intolerant to at least one prior therapy, or refuse standard therapy
    • For those patients receiving phlebotomy only, the frequency over the past year must be at least one phlebotomy every 3 months.
  • Undergone phlebotomy and attained a Hct \< 47% (men) or \< 45% (women) (or pre-specified Hct count that is tolerable) within 14 days prior to the start of study treatment
  • Cessation of myelosuppressive agents prior to initiation of study treatment (unless approved by Geron Medical Monitor for unusual circumstances)

    • Hydroxyurea or anagrelide: Cessation 1 day prior to initiation of study treatment. Consideration to the timing of cessation of this therapy prior to the start of study treatment should take into account the requirement for phlebotomy.
    • INF-α or pegylated- INF-α: Cessation 4 weeks prior to initiation of study treatment
  • Laboratory criteria (within 14 days of first study drug administration):

    • Platelets > the lower limit of normal (LLN)
    • ANC ≥ 1500/μL

General Criteria (All Patients)

  • Willing and able to sign an
  • Male or female, aged 18 years or older
  • performance status 0-2
  • Laboratory criteria (within 14 days of first study drug administration):

    • (or PT) and aPTT \< 1.5 x the (ULN)
    • Serum creatinine ≤ 2 mg/dL
    • Serum \< 2.0 mg/dL (patients with Gilbert's syndrome: serum bilirubin \< 3 x ULN)
    • (SGOT) and ALT (SGPT) ≤ 2.5 x ULN
    • Alkaline phosphatase \< 2.5 x ULN
  • Any toxicity from previous cancer treatments and/or major surgery must have recovered to Grade 0-1 prior to initiation of study treatment
  • Women of must have a negative pregnancy test and agree to use effective during and for at least 12 weeks after the last study treatment with imetelstat
  • Male patients must agree to use effective birth control for themselves or their partner during and for 12 weeks after the last study treatment with imetelstat.

Exclusion criteria

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from screening and study entry:

  • Women who are pregnant or breast feeding
  • Prior stem cell transplantation
  • therapy within 4 weeks prior to first study drug administration
  • cardiovascular disease or condition including:

    • Uncontrolled congestive heart failure (CHF)
    • Need for anti-arrhythmic therapy for a ventricular arrhythmia
    • Clinically significant severe conduction disturbance per the Investigator's discretion
    • Ongoing angina pectoris requiring therapy
    • (NYHA) Class II, III, or IV cardiovascular disease (see Appendix E)
  • Known positive serology for (HIV)
  • Serious co-morbid medical conditions, including active or chronically recurrent bleeding, clinically relevant active infection, cirrhosis, and chronic obstructive or chronic restrictive pulmonary disease per the Investigator's discretion
  • Any other severe, acute, or chronic medical or psychiatric condition, laboratory abnormality, or difficulty complying with protocol requirements that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    imetelstat

    Induction dosing of 9.4 mg/kg weekly, followed by intermittent maintenance dosing.

    Drug: Imetelstat

Interventions

06

What researchers measure

Primary outcomes

  1. Hematologic Response

    Primary objectives are as follows: ET patients - best hematologic response within the first year of therapy and PV patients - maintenance of Hct \< 45% in men and \< 42% in women (or pre-specified Hct count that is tolerable) without phlebotomy or myelosuppressive therapy within the first year of therapy. Secondary objectives, to determine the durability of hematologic response and to determine the rate of phlebotomy required within the first year of therapy.

    Time frame: From time of first dose (cycle 1 day 1) through end of study (12 mos after last participant is dosed)

Secondary outcomes

  1. Safety and tolerability: Number of Patients with Hematological Toxicities, Non-Heme Grade 3 and 4 AEs, and Hemorrhagic Events

    The safety and tolerability of imtelstat will be assessed by the incidence, nature, relatedness and severity of adverse events, laboratory abnormalities and vital signs.

    Time frame: From time of first dose (cycle 1 day 1) through end of study (12 mos after last paricipant is dosed)

07

Study locations

12 sites
  • City of Hope
    Duarte, California 91010, United States
  • MDACC - Orlando
    Orlando, Florida 32806, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Johns Hopkins University - Bunting Blaustein Cancer Research Building
    Baltimore, Maryland 21205, United States
  • Saint Francis Hospital
    Greenville, South Carolina 29601, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University Hospital of Essen - West German Cancer Center
    Essen, Germany
  • Medizinische Klinik II, Abt. Hämatologie und Onkologie - Johann Wolfgang Goethe Universität
    Frankfurt, D-60590, Germany
  • SLK-Kliniken GmbH
    Heilbronn, Germany
  • Hematology Oncology Center - Ludwig-Maximilians, University Munich Medical School
    Munich, 80331, Germany
  • University Hospital Regensburg - Uniklinik Regensburg
    Regensburg, Germany
  • INSELSPITAL, University Hospital Bern
    Bern, CH - 3010, Switzerland
08

References and documents

Publications

  • Oppliger Leibundgut E, Haubitz M, Burington B, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, Roth A, Snyder DS, Baerlocher GM. Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat. Haematologica. 2021 Sep 1;106(9):2397-2404. doi: 10.3324/haematol.2020.252817. PubMed 32732354 ↗
  • Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, Roth A, Daskalakis M, Burington B, Stuart M, Snyder DS. Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. N Engl J Med. 2015 Sep 3;373(10):920-8. doi: 10.1056/NEJMoa1503479. PubMed 26332546 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Oct 2013 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2010
First posted
Nov 18, 2010
Start
Dec 2010
Primary completionActual
Oct 2013
CompletionActual
Apr 2015
Results delay requested
Apr 14, 2015
Last update
Jan 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01243073
Lead sponsor
Geron Corporation
Responsible party
Sponsor
First posted
Nov 18, 2010
Start date
Dec 2010
Primary completion
Oct 2013
Completion
Apr 2015
Last update
Jan 26, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imetelstat

Start the discussion